Bayer: Science For A Better Life

United States of America

Women's Health Information for Grant Submissions

Intended Audience: Healthcare Professionals including Obstetricians, Gynecologists, Physician Assistants, and Nurses specializing in Women's Health (NPs, APNs, CMs, and RNs); Primary Care Physicians and Family Medicine Practitioners

Bayer TA Rationale for Educational Support:

  • Educate health care professionals on the broad impact of menopause on women in both their personal and professional lives, including physical, emotional, and financial effects.
  • Provide guidance on the identification, counseling, and management of women as they enter the menopausal transition.
  • Expand awareness of the role of the hypothalamic KNDy system on vasomotor symptoms, sleep disorders, and mood disturbances.

Preferred Format:

  • Enduring
  • Downloadable slides
  • Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
  • Podcast
  • Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status


Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability


Publication References


  1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health qual Life Outcomes 2005;3:47.
  2. Whiteley J, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J of Women’s Health 2013:22:983.
  3. Dominus S. Women have been misled about menopause. New York times. Published Feb 1, 2023.
  4. United States Census Bureau. Population estimates (sex by age), 2008.
  5. Hill K. The demography of menopause. Maturatas 1996;23:113.
  6. Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021;28:875.
  7. Thurston RC, Chang Y, Buysse DJ, et al. Hot flashes and awakenings among midlife women. Sleep 2019;42:zsz131.
  8. Williams RE, Kalilani L, Britt Dibenedtti D, et al. Frequency and severity of vasomotor symptoms among peri-and postmenopausal women in the United States. Climacteric 2008;11:32.
  9. Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117::1095.
  10. Woods NF , Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016;23:158.
  11. NAMS Position Statement: The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767.
  12. ACOG Practice Bulletin: Management of menopausal symptoms. Number 141, Jan 2014 (reaffirmed 2018).
  13. Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative study results. Menopause 2018;26:588.
  14. Optum Claims Data 2020: US VMS Patient Market Landscape, accessed January 2023.
  15. Biglia N, Bounous VE, De Seta F, et al. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience 2019;13:909.
  16. Orleans RJ, Li L, Kim M-J, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014;370:1777.
  17. Bayer Data on File. Source Symphony Health. Accessed April 2023.
  18. Rance NE, Dacks PA, Mittleman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34:211.
  19. Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalamus of postmenopausal women. Endocrinology 1991;128:2239.
  20. Padilla SL, Johnson CW, Barker FD, et al. A neuronal circuit underlying the generation of hot flushes. Cell Rep 2018;24:271.
  21. Hrabovszky E, Borsay BA, Racz K, et al. Substance P immunoreactivity exhibits frequent colocalization with kisspeptin and neurokinin B in the human infundibular region. PLoS One 2013;8:e72369.
  22. Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041.
  23. Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023;30:239.
  24. Modi M and Dhillo WS. Neurokinin B and Neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes. Semin Reprod Med 2019;37:125.
  25. Christianson MS, Ducie JA, Altman K, et al. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause 2013:20:1120.
  26. Richard-Davis G, Singer A, King DD, Mattle L. Understanding attitudes, beliefs, and behaviors surrounding menopause transition:results from three surveys. Patient Related Outcome Measures 2022:13:273.